Bucladesine, PKA activator, is a cyclic nucleotide derivative that mimics the action of endogenous cAMP and is capable of permeating the cell membrane. It has vasodilator properties and is used as a cardiac stimulant.

In cultured rat hepatocytes, Bucladesine has the affection of inhibited of NF-κB-binding activity and inducible nitric oxide synthase expression. Bucladesine also inhibits TNFα-induced hepatocyte apoptosis by suppressing FADD up-regulation.

In a mouse model, bucladesine (600 nM, i.p.) reverses lead acetate- and zinc chloride-induced impairments of avoidance memory retention.

Animal: Mice. Formulation: water/DMSO (9:1). Dosages: 600 nM. Administration: i.p.

16980-89-5

C18H23N5NaO8P

491.373

Dibutyryl-cAMP;Dibutyryl-cAMP sodium salt;DC2797;Bucladesine;dbcAMP;Bucladesine sodium salt;布拉地新钠盐;Sodium dibutyryl cAMP;Bucladesine sodium

[1]Prapong T, et al. Exp Neurol. 2001, 167(1), 59-64. [2]Xu C, Zhao W, Huang X, et al. TORC2/3-mediated DUSP1 upregulation is essential for human decidualization[J]. Reproduction. 2021, 1(aop). [3]Biol Trace Elem Res. 2015, DOI10.1007/s12011-015-0399-z [4]Harbrecht BG, et al. J Surg Res. 2001, 99(2), 258-264. [5]Wang Y, et al. Apoptosis. 2006, 11(3), 441-451.

[1]Xu C, Zhao W, Huang X, et al. TORC2/3-mediated DUSP1 upregulation is essential for human decidualization. Reproduction. 2021, 1(aop).

H2O:49.1 mg/mL (100 mM)
DMSO:49.1 mg/mL (100 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years